Last reviewed · How we verify

NCT06202300: CAD-MAP

Myocardial and Arterial Phenotype of Coronary Artery Disease

Status unknown Last updated 11 January 2024
What this trial tests

trial testing Inflammation burden in Coronary Artery Disease in 5,000 participants. Status unknown.

Timeline
12 March 2023
Primary endpoint
30 June 2024
30 June 2024

Quick facts

Lead sponsorBeijing Anzhen Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment5,000
Start date12 March 2023
Primary completion30 June 2024
Estimated completion30 June 2024
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Anzhen Hospital

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CAD-MAP (Myocardial and Arterial Phenotype of Coronary Artery Disease) registry is initiated with the goal to describe the cardiac imaging map including epicardial coronary artery, coronary microcirculation and myocardium, and further exploring the prognostic value of multidimensional imaging biomarkers and predictive models in CAD patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Beijing Anzhen Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06202300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing